TSLA
Tesla
-- 462.280 NVDA
NVIDIA
-- 140.220 PLTR
Palantir
-- 82.380 AMD
Advanced Micro Devices
-- 126.290 MSTR
MicroStrategy
-- 358.180 
$Nurix Therapeutics (NRIX.US)$ NRIX exhibits a moderately hi...
NRIX exhibits a moderately high risk level primarily due to its financial underperformance, demonstrated by substantial net losses and negative free cash flow, indicating financial instability. Additionally, its PE ratio is negative, reflecting market uncertainties regarding future profitability. Despite positive news catalysts, the absence of profitability and the high volatility in the biotechnology sector compounds the riskiness of the stock. Recent positive analyst sentiment and proximity to the 52-week high provide optimism, yet they do not fully mitigate existing financial shortcomings. Hence, traders should approach any investment in NRIX with caution, balancing the potential reward of breakthrough successes against the inherent financial risks.
Key Levels
Support Levels: The clear support level is approximately $26, as identified from recent consolidation. This price is important as it acts as a floor where buyers are likely present.
Resistance Levels: The 52-week high at $27.07 serves as a critical resistance level, presenting a potential cap due to prior peak prices. Breaking this level can signal strength for further highs.
Intermediate Levels: Recent chart activity suggests $24.59 as an important stop level to observe for shifts in trading bias, ensuring a disciplined risk approach.
Support Levels: The clear support level is approximately $26, as identified from recent consolidation. This price is important as it acts as a floor where buyers are likely present.
Resistance Levels: The 52-week high at $27.07 serves as a critical resistance level, presenting a potential cap due to prior peak prices. Breaking this level can signal strength for further highs.
Intermediate Levels: Recent chart activity suggests $24.59 as an important stop level to observe for shifts in trading bias, ensuring a disciplined risk approach.
Stretegy
Bias: Long
Entry : $27.00
Robust Profit Target: $35.72
Stop : $24.593
Allocation : If i have business startup capital ,$10,000 reference ce capital, i will allocate 13.7%
Risk:Reward: 1:3.63
Given the company’s current financial health juxtaposed with clear technical levels, caution is advised, along with a defined entry and exit strategy. Additionally, it may be beneficial to continuously monitor developments in its sector and any further corporate advancements to optimize trading decisions. Its recent positive technical and news aspects provide encouragement warranting a trading opportunity consideration, albeit with a guided discipline and risk safeguard.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
#unprofitable part time trader trying to make breakeven money aiming for consistent 5- 20% or little more not 1000%.
954Followers
1277Following
5627Visitors
Follow